Is the low-thalidomide dose MPT regimen beneficial?
Chang-Ki
CK
Min
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use*; D009101:Multiple Myeloma / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use; D013792:Thalidomide / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D018906:Antineoplastic Agents, Alkylating; D013792:Thalidomide; D008558:Melphalan; D011241:Prednisone